Abstract
Purpose: To investigate the influence of a combination of abiraterone and prednisone on serum chromogranin A (CgA) and neuron-specific enolase (NSE) in patients with metastatic castrationresistant prostate cancer (mCRPC) without previous chemotherapy, so as to provide reference data for drug therapy of prostate cancer.
 Methods: A total of 103 mCRPC patients without chemotherapy from January 2013 to March 2017 were included in this retrospective study. Seventy-one (71) patients received prednisone combined with abiraterone (study group), while 32 patients accepted prednisone (control group). The CgA, NSE and prostate-specific antigen (PSA) in the two groups were monitored, while PSA progression-free survival (PSA-PFS), radiographic PFS (rPFS), and overall survival (OS) were determined during follow-up.
 Results: PSA-PFS, rPFS and OS in the study group were significantly higher than those in the control group (p < 0.05). The increased proportion of CgA or NSE in the study group was significantly lower than that in the control group at 6 months of treatment (p < 0.05). The occurrences of NED before treatment and 6 months after treatment were both independent predictors of PSA and radiographic progression in the study group (p < 0.05).
 Conclusion: The combination of prednisone and abiraterone is helpful for prognosis in mCRPC patients that are not on chemotherapy. The occurrence of NED predicts mostly poor prognosis of mCRPC patients on a combination of abiraterone and prednisone
Highlights
Prostate cancer is the most frequently-diagnosed malignancy in males
Seventy-one (71) patients were treated with prednisone combined with abiraterone, while 32 patients were treated with prednisone
The current study showed that the duration of endocrine therapy before the investigation was related to the elevation of chromogranin A (CgA) and neuron-specific enolase (NSE) after 6-cycle treatment
Summary
Prostate cancer is the most frequently-diagnosed malignancy in males. Most patients with prostate cancer are at the advanced stage at the point of definite diagnosis. Castration method is a standardized suppressive treatment in patients with aggressive prostate cancer; it decreases tumor burden, lowers PSA level, and inhibits the secretion of testosterone [1]. Research has shown that castration has poor prognosis in mid- and long-term outcomes: almost all the. -©---2-0--1--9--Y--a--n-g---K--,--L-i--T--,-G---a-o---Z--,-Z--h--a--n-g---W---.-T--h--is---w--o--rk---is---l-ic--e-n--s-e--d---u-n--d--e-r--t-h--eT--rC-o-r-pe--a-J-t-iPv--eh--aC-r-o-m-m--R-m-e-os--,n-Ms---Aa--tr-tcr-i-hb--u2-t-0i-o1-n-9--;4--1.-08--(-3--)-:-6--3-1 International License patients would deteriorate into metastatic castration-resistant prostate cancer (mCRPC) [2]. The tumor is still sensitive to androgen after becoming mCRPC. A new generation of endocrine drugs such as abiraterone is used to inhibit androgen receptor axis, which helps control mCRPC [3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
